Currently out of the existing stock ratings of Scott Schoenhaus, 75 are a BUY (92.59%), 6 are a HOLD (7.41%).

Scott Schoenhaus

Work Performance Price Targets & Ratings Chart

Analyst Scott Schoenhaus, currently employed at KEYBANK, carries an average stock price target met ratio of 41.97% that have a potential upside of 18.98% achieved within 79 days. Previously, Scott Schoenhaus worked at STEPHENS.

Scott Schoenhaus’s has documented 154 price targets and ratings displayed on 17 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on ABCL, Abcellera Biologics at 11-Jul-2024.

Wall Street Analyst Scott Schoenhaus

Analyst best performing recommendations are on BNFT (BENEFITFOCUS).
The best stock recommendation documented was for RXRX (RECURSION PHARMACEUTICALS) at 7/13/2023. The price target of $15 was fulfilled within 6 days with a profit of $2.56 (20.58%) receiving and performance score of 34.3.

Average potential price target upside

of $34.14 (16.59%) on VEEV (VEEVA SYSTEMS).
of $22.35 (10.56%) on TDOC (TELADOC).
of $21.25 (10.83%) on IQV (IQVIA HOLDINGS).

TDOC Teladoc VCRA Vocera Communications VEEV Veeva Systems IQV IQVIA Holdings OMCL Omnicell ALIT Alight GDRX Goodrx Holdings HQY HealthEquity RCM R1 RCM BNFT Benefitfocus PGNY Progyny PHR Phreesia RXRX Recursion Pharmaceuticals HCAT Health Catalyst ABCL Abcellera Biologics ABSI Absci Corp SDGR Schrodinger

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

George Hill (DEUTSCHE BANK)